Two innovative genetic tests Pill Protect® and Cypass® reimbursed by supplementary insurance

As of November 1st, 2016, Gene Predictis’ genetic tests Pill Protect® and Cypass® are reimbursed by supplementary healthcare cover PRIMEO from Helsana, the leading insurance group in Switzerland. These tests allow to evaluate, for every individual, the risk of adverse drug events by integrating both patient’s genetics and clinical data. This represents a significant step forward towards personalization of care for patients on one hand and preventive medicine on the other.


Gene Predictis wins the European Venture Contest 2015

Gene Predictis SA, a Swiss precision medicine company offering tools to optimize drug treatments, is a winner of the European Venture Contest 2015. The company was selected from over 1’000 companies in high technology sector, by an international investors jury composed of over 100 investors and business angels, based on its technology and business opportunity, as one of the most promising companies in Europe in the Life Sciences field.

The contest was organised by Europe Unlimited and took place in Düsseldorf, Germany, on December 7 and 8, 2015.

PR EVS Award Winners


Gene Predictis® closes its first financing round

Gene Predictis®, a Swiss precision medicine company, announces the closing of its first financing round. The company has raised CHF 0.5 million from a strategic investor that is a major player in the Swiss health care ecosystem.

The proceeds will be used to support marketing and commercialization in Switzerland of its leading product, Pill Protect®, as well as for the CE-IVD labelling of Pill Protect® to assure its timely launch on the EU market. Pill Protect® is an innovative medical test that uses genetic data to identify women at risk of developing blood clots (thrombosis) when using contraceptive pills. The test was launched in Switzerland in mid-September 2015 and has received very promising initial market acceptance.

The closing of this initial investment follows the successful achievement of a series of milestones in 2015, including successful clinical validation study for Pill Protect®, Pill Protect® patent filing and the launch of the product on the Swiss market.

Gene Predictis® pursues an additional investment with a financial partner mainly to fund the launch of Pill Protect® and Cypass®, another strategic product, in markets outside of Switzerland.

announcement financing


Pill Protect®: The first clinically validated test for identifying women at risk of developing deep vein thrombosis (DVT) under contraceptive pills

Gene Predictis®, a Swiss precision medicine company, has completed an international clinical validation study for Pill Protect®, an innovative medical test that uses genetic data to identify women at risk of developing blood clots (thrombosis) when using contraceptive pills. The test was shown to identify over 8 times more women at risk than today standard of care, making Pill Protect® the best available test. Already proposed in Switzerland and reimbursed by the insurances, the test helps to identify women at risk of thrombotic disease and facilitate the decision process for medical doctors helping them to propose the most optimal and safest contraceptive pill/method for every woman.

Press release_Pill Protect_september 2015_ang



Gene Predictis wins the Alpine High-tech Venture Forum Award 2015

Gene Predictis is a winner of the 2015 Alpine High-tech Venture Forum Award. The company was selected by an international investors jury, based on its technology and business opportunity, as one of the most promising companies in the Life Sciences field.

Organised by Europe Unlimited and supported by Eureka High-Tech Investment Programme and Canton de Vaud, The Alpine High-tech Venture Forum promotes innovative companies in Life Sciences, Clean Technology and Information Technology sectors.


Gene Predictis SA elected as one of the top 20 medtech and healthcare companies in Europe

Gene Predictis SA was selected, by the expert committee of the Tech Tour and International Venture Club, as one of the top 20 medtech and healthcare companies in Europe. The company was presented during the Healthtech Summit in Lausanne on June 23&24, 2014.

About the Tech Tour
The Tech Tour is an independent, not-for-profit organization composed of key contributors to the high technology industry. The organization recognizes that continued prosperity in Europe lies in its ability to transform today’s innovative projects into tomorrow’s global technology leaders.

About the International Venture Club
The International Venture Club was founded in 2011 as the collaborative platform of leading venture investors promoting successful international investments. Its objectives are to 1) share better practices, 2) build coinvestor trust and relations, 3) foster new funding and investment opportunities through joint actions and PR, 4) grow promising companies with corporate partners and co-investors and 5) keep a smart window and support to emerging innovative companies.


Gene Predictis in press

Le Temps


Gene Predictis SA received the CTI Start-Up Label certification

Gene Preditis has been awarded the CTI Start-Up Label on September 10th, 2013  by the Commission for Technology and Innovation CTI, Swiss Confederation. The Start-up Label is a seal of quality, a certificate of achievement, and a sign of credibility and readiness for sustainable growth.


Gene Predictis in press

We are happy to share with you our recent press release:


ARC_20130802 Vendredi – Express – UNE – pag 1
ARC_20130802 Vendredi – Express – Suisse – pag 15


Gene Predictis SA inaugurates new laboratories at Science Park EPFL in Lausanne

In August 2012, Gene Predictis SA moved its headquarters and laboratories to the Science Park EPFL in Lausanne. Today, we have a pleasure to inaugurate our new space and present you our products.


Gene Predictis protected name is under attack

We have recently discovered that our company name and registered trademark GENE PREDICTIS are used by third parties without our consent and associated to products and services which have nothing to do with Gene Predictis SA. In addition, misleading photographs of our partners, locations, collaborators and clinics are used without prior consent. We are currently investigating and intend to take legal action as appropriate. Products and services named after Gene Predictis DO NOT INCLUDE any cosmetics or other biological or chemical preparation. If you have any doubts about the origin of products or services bearing the Gene Predictis name please feel free to call at +41 26 466 15 45 or e-mail us at


Gene Predictis proposes the Carbamazepine-sensibility test

Novartis Pharma Suisse SA published on 1st of March 2012 an important pharmacovigilance communication concerning Tégrétol (carbamazepine and its generics (Carsol CR, Neurotop retard, Timonil): before a prescription of Tégrétol (or its generics) each patient shall be tested for the presence of HLA-A*3101 allele. The aim of the test is to evaluate an individual risk to develop adverse drug reactions to carbamazepine.

Gene Predictis SA has a pleasure to inform you that we set up carbamazepine-sensibility test in our laboratory and you can request it at present. We are the first laboratory in Switzerland proposing this test.


Portal Cypass™ – The unique interactive tool to optimise drug prescription in function of genotype

Gene Predictis developed a unique, interactive, and user-friendly web-based portal destined to medical doctors, which allows tailoring of drug prescription in function of genetics. The portal integrates results of our genetic test CypassTM and the current knowledge on metabolism of drugs, as well as on drug-drug interactions, to ensure optimal efficiency of medicaments while reducing the risk of adverse effects.

If you are interested to learn more about this tool and to use it, please contact us.


The forthcoming Gene Predictis event

In collaboration with the pharmacy Sen’Su in Lausanne, we are organizing a conference focused on Genetics of food intolerances. It is taking place on 26th of April, 2012 in Lausanne.

Please download the program and the invitation using the following link: invitation evenment SenSu



Dr. Goranka Tanackovic new CEO

Dr. Goranka Tanackovic joined “Gene Predictis” at CEO position from September 2011.  Combining her strong entrepreneurial spirit and past experience, she is determined to further develop projects of “Gene Predictis” and contribute to its growth.

Dr. Tanackovic obtained M.Sc. degree in both Biology and Chemistry from the University of Osijek, Croatia. She then studied human hereditary disorders and, in 1999, earned Ph.D. in Biology from the University of Zagreb, Croatia. In 2000 she moved to Geneva, Switzerland, where she worked in the filed of RNA research and was awarded her second Ph.D. in Biology in 2004, from the University of Geneva. Her postdoctoral research was focused on molecular mechanisms involved in various genetic diseases. During her academic career, Dr. Tanackovic successfully led various research projects, obtained numerous research grants, and results of her work are recognized through the publications in high-impact per-reviewed journals.

In parallel with her Ph.D. studies, Dr. Tanackovic successfully completed entrepreneurship program of “Create” Switzerland (2002) and was one of the winners of “Venture Leaders” program in 2003. In this frame, she also successfully completed an entrepreneurship program at Babson College, Wellesley, USA (2003).


Dr Joëlle Michaud new laboratory director

Dr Joëlle Michaud from CIG (Lausanne) has joined Gene Predictis SA in July. Dr. Michaud who has 10 years practice in genetics and molecular biology will replace Dr Karin Brunschwig who is leaving the company in September.

Dr Michaud obtained her Master in medical genetics from the University of Geneva and her PhD in medical and molecular biology in 2005 at the Walter and Eliza Hall Institute in Melbourne, Australia. She then came
back to Switzerland and worked as a research fellow at the University of Lausanne.

During her academic career she published in high quality journals such as Blood, Genomics and BMC Genomics. She has a strong background in genetics, genomics, molecular biology and bioinformatics.


Annabel McQuillan joins the Scientific board

Dr. Annabel McQuillan joins Gene Predictis and will bring her experience and vision on how pharmacogenetics could help to improve psychiatric medicine.

Dr McQuillan was born in Edinburgh and studied medicine at the University of Glasgow. After internships in medicine and surgery she moved to Geneva to do her doctoral thesis in gastroenterology. Initially because of an interest in psychosomatic medicine she trained as a psychiatrist.

Her subsequent clinical interest in mood disorders, Borderline Personality Disorder (BPD) and suicidal behavior led to a specialized training with Professor M. Linehan in Seattle. On her return she developed the CARE Program, an out-patient treatment facility within the Department of Psychiatry. This program delivers innovative evidenced based treatment combing a modern psychotherapeutic approach with pharmacological treatments for patients suffering from BPD and ongoing suicidal and self-harming behaviors. Dr McQuillan has taught for many years on both clinical and theoretical aspects of these pathologies, as well as authoring scientific papers and conferences.

Over the years Dr McQuillan has participated actively in implementing novel treatment strategies in an attempt to improve clinical outcomes and particularly to reduce hospitalization rates. She is currently working in psychopharmacology.


Gene Predictis will benefit from CTI’s expertise

Gene Predictis has been accepted in the Swiss Commission for Technology and Innovation (CTI) start-up coaching program.
CTI promotes innovative development of young Swiss companies, providing professional expertise in business management and development.

Given this support, Gene Predictis does aim to strengthen its ability to address customers’ needs in the field of pharmacogenetics and develop new solutions to offer accessible genetic passports (CYPASS ™) that will allow physicians to individualise drug prescription.

This is a cardinal issue, given that adverse drug reactions (ADR) are involved in up to 7% of hospital emergency admissions in Switzerland and up to 18% in the US. Moreover, fatal ADR brings about 3% of the Swedish death rate, and it is the 4th most common cause of death in US hospital patients.


Partnership with EMBLEM

Gene Predictis’s announces a partnership with the Enterprise Management Technology Transfer EMBL Company , in Heidelberg, Germany. The EMBL is the European Centre for Molecular Biology.
Cooperation aims at the development of innovative technologies to appraise, in a faster and accurate way, findings of fundamental genetics and convey them to the patient/customer.
Dr Lars Steinmetz, chairman of the Functional Genomics Department, and member of our scientific board, is heading to develop innovative devices for genetics diagnosis leading to application in personalised medicine.

Predictive medicine inferred from genetics